Vice-Chairman of PhIRDA Drug R&D Specialty Committee, CEO and CSO of RemeGen
Professor Fang Jianmin got his PhD in Biology from Dalhousie University and worked as a post-doctoral fellow focusing on cancer research at Harvard Medical School. He is the co-founder, CEO, and CSO of RemeGen Co., Ltd. and the founder and chairman of MabPlex International Ltd. In addition, Dr. Fang serves as professor and PhD supervisor at School of Life Science and Technology of Tongji University.Dr. Fang was recognized as Taishan Scholar by the Shandong Provincial Government and member of the scientific expert committee of the National Major Scientific and Technological Project for “Major Drug Innovations” of China. Dr. Fang has been committed to the drug innovations for major diseases of tumor and autoimmune, and his research results have been published in Nature Biotechnology, PNAS, Cancer Research, and Molecular Therapy, etc. As the inventor of Telitacicept (RC18), Disitamab vedotin (RC48), RC28, and Conbercept, he owns more than 40 invention patents, including several global patents for antibody-based drug.